/
PAHC
$31.81+$0.12 (+0.38%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.3B
41M shares
52-week range
$25.33 – $60.08
19% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$2.93
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $820.0M | $828.0M | $800.4M | $833.4M | $942.3M | $977.9M | $1.02B | $1.30B |
| Cost of revenue | $553.1M | $563.4M | $543.5M | $562.0M | $656.9M | $679.7M | $704.6M | $896.3M |
| Gross profit | $266.9M | $264.6M | $256.9M | $271.4M | $285.4M | $298.2M | $313.1M | $399.9M |
| Gross margin | 32.5% | 32.0% | 32.1% | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| R&D | $10.0M | $12.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $98.9M | $73.3M | $69.2M | $74.9M | $79.0M | $71.8M | $53.3M | $110.5M |
| EBITDA | $128.6M | $112.7M | $101.6M | $110.2M | $117.1M | $106.0M | $69.1M | $146.8M |
| Net income | $64.9M | $54.7M | $33.6M | $54.4M | $49.2M | $32.6M | $2.4M | $48.3M |
| Net margin | 7.9% | 6.6% | 4.2% | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| EPS (diluted) | 1.61 | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.5B | $3.07 | $3.03–$3.10 | 3 |
| 2027 | $1.5B | $3.34 | $3.19–$3.49 | 3 |
| 2028 | $1.6B | $3.68 | $3.64–$3.71 | 1 |
| 2029 | $1.6B | $4.36 | $4.31–$4.39 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Phibro Animal Health Corporation Class A
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
www.pahc.com- Employees
- 2,475
- IPO / List date
- Apr 11, 2014
- HQ
- TEANECK, NJ
Held by traders on TradeandTell
No one on the platform currently holds PAHC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 576,735 | $31.9M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 1.51% ($0.48/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-03 | $0.1200 | 2026-06-24 |
| 2026-03-04 | $0.1200 | 2026-03-25 |
| 2025-11-26 | $0.1200 | 2025-12-17 |
| 2025-09-03 | $0.1200 | 2025-09-24 |
| 2025-06-04 | $0.1200 | 2025-06-25 |
| 2025-03-05 | $0.1200 | 2025-03-26 |
| 2024-11-27 | $0.1200 | 2024-12-18 |
| 2024-09-04 | $0.1200 | 2024-09-25 |
| 2024-06-05 | $0.1200 | 2024-06-26 |
| 2024-03-05 | $0.1200 | 2024-03-27 |
Recent trades on TradeandTell
No one on the platform has traded PAHC yet.
